Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-In-Class CD20xCD3 Bispecific IGM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

64th American Society of Hematology (ASH) Annual Meeting and Exposition — December 10-13, 2022